We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Roche has partnered with Dyno Therapeutics to develop adeno-associated virus (AAV) vectors for gene therapies for nervous system diseases and liver-directed treatments, part of the Swiss drugmaker’s push to expand into gene therapies. Read More
Barely more than one in four air cargo companies that will be involved in distributing COVID-19 vaccines are well-prepared to do so, a new survey has found. Read More
The British Embassy in Bangkok announced Monday that Thailand will pitch in to manufacture AstraZeneca’s COVID-19 vaccine candidate to bolster the supply in southeast Asia. Read More
Mallinckrodt filed for bankruptcy protection Monday as the company faces billions of dollars in legal liabilities over its role in the nation’s opioid epidemic. Read More
Arrowhead Pharmaceuticals and Japanese drugmaker Takeda have struck a $1 billion licensing deal to develop a new treatment for alpha-1 antitrypsin-associated liver disease (AATLD). Read More
The price of dexamethasone, now in demand as a COVID-19 treatment, has increased dramatically in recent months and is poised to go up, the research group 46Brooklyn said. Read More
Teva Pharmaceuticals is back on the hook for $235 million in damages for infringing on GlaxoSmithKline’s patent for its blood pressure drug Coreg (carvedilol), thanks to a federal appeals court ruling. Read More
The deal gives BMS mavacamten, MyoKardia’s investigational treatment for obstructive hypertrophic cardiomyopathy, a chronic heart disease afflicting up to 200,000 individuals in the U.S. and the EU. Read More
AbbVie, Abbott Laboratories, Unimed Pharmaceuticals and Besins Healthcare are off the hook for $448 million they would have had to pay to the Federal Trade Commission (FTC), thanks to a favorable ruling by a federal appeals court. Read More